Kiora Pharmaceuticals
KPRX
17 hedge funds and large institutions have $5.97M invested in Kiora Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 11 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
43.15% more ownership
Funds ownership: 4.72% → 47.87% (+43%)
24% less capital invested
Capital invested by funds: $7.87M → $5.97M (-$1.9M)
26% less funds holding
Funds holding: 23 → 17 (-6)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$933K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$235K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$45K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$38.8K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$93 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$297K |
| 2 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$56.5K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$17.6K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.3K |
| 5 |
HF
HRT Financial
New York
|
-$16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | -$42 | -7 | Closed |
|
|
AFG
27
Albion Financial Group
Salt Lake City,
Utah
| – | -$5 | -1 | Closed |
|
28
Fidelity Investments
Boston,
Massachusetts
| – | -$5 | -1 | Closed |
|
KPRX Hedge Fund Activity: Q2 2024 in Review
17 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q2 2024, worth a combined $5.97M — down 24% from $7.87M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of KPRX and 5 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $933K. The largest seller was Alyeska Investment Group, cutting an estimated $297K.
- 17 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q2 2024, down from 23 in Q1 2024.
- Funds reported $5.97M of Kiora Pharmaceuticals stock for Q2 2024, down 24% quarter-over-quarter.
- 5 funds opened new Kiora Pharmaceuticals positions in Q2 2024 and 11 closed out, a net change of -6 holders.
- The largest Kiora Pharmaceuticals buyer in Q2 2024 was Stonepine Capital Management, an estimated $933K added.
- The largest Kiora Pharmaceuticals seller in Q2 2024 was Alyeska Investment Group, an estimated $297K sold.
Based on aggregated 13F filings for Q2 2024.